This is from their last adult clinical/trial study, clearly RAP uses trial and study interchangeably. You still need to cough and get confirm whether the diagnosis are correct or not......so I don't think you are correct there. They are way pass gathering data and training the algorithm.
"Correctly detected lower respiratory tract disease in 84% of adult patients initially diagnosed as clear by experienced clinicians using stethoscopes"
"ResApp’s US paediatric clinical study is also progressing well. SMARTCOUGH-C is a prospective, multi-site, double-blind study that will evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood pneumonia and other respiratory conditions from cough sounds."
- Forums
- ASX - By Stock
- RAP
- Conference Call Summary
Conference Call Summary, page-322
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 255 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online